UNSPSC 51386604: Dibucaine/hydrocortisone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386604 Dibucaine/hydrocortisone is a Commodity code that in practice covers a much broader range of pharmaceutical and over-the-counter products than its specific name suggests; state and local health authorities, cooperative purchasing alliances, and specialized health agencies are using it to tag solicitations for generic pharmaceuticals, naloxone, drug deactivation systems, and OTC products for community health and pharmacy benefit programs. The work being solicited includes bulk procurement of naloxone and harm-reduction equipment for community health initiatives, direct-to-manufacturer prescription programs through state health agencies, and multi-state cooperative purchasing agreements for generic pharmaceuticals and OTC inventory to supply state and local government health facilities. Issuing bodies range from county health departments and state HHS agencies to regional cooperative purchasing organizations serving multiple states; Seminole County, Florida and the Texas Health and Human Services Commission have posted recent solicitations under this code, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers a two-year RFP for multi-source generics and OTC products open to participating state and local agencies across multiple states including Oregon.

Activity is concentrated in the Southeast and Upper Midwest; Seminole County released an IFB on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly delivery to Sanford, Florida, while the Texas HHS Commission posted an RFI on April 3, 2026 exploring direct-to-manufacturer prescription models with vendors experienced in self-insured group health and government sector contracting. MMCAP's most recent RFP, posted January 20, 2026 with a March 26, 2026 proposal deadline, covers generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencora, Cardinal Health 110 and 112, and Morris & Dickson) across member states, with awards effective July 1, 2026 and pricing evaluated at 75 percent weight. All three solicitations require FDA compliance, cGMP certification where applicable, E-Verify or equivalent documentation, and insurance coverage including workers' compensation and commercial general liability.